DEPIXUS

In News

New Study Demonstrates Power of Depixus’ Scalable Single Molecule Interactomics Platform to Accelerate RNA-Targeted Drug Development - BioSpace

BioSpace - Sep 25, 2024

Depixus and Daiichi Sankyo Collaborate to Produce RNA-Targeted Drugs - Inside Precision Medicine

Inside Precision Medicine - Dec 12, 2023

Depixus Announces Strategic Collaboration With Daiichi Sankyo to Use MAGNA™ Technology to Accelerate RNA-targeted Drug Discovery - Business Wire

Business Wire - Dec 12, 2023

Daiichi Sankyo and Depixus partner to accelerate RNA-targeted drug discovery - Pharmaceutical Technology

Pharmaceutical Technology - Dec 13, 2023

Depixus Raises EUR 30.6M (USD 35.4M) in Series A Financing - News-Medical

News-Medical - Dec 15, 2021

Daiichi Sankyo taps Depixus to speed RNA drug discovery - pharmaphorum

pharmaphorum - Dec 13, 2023

CoNAN projects: new generation of microchip-based tools for genetic analysis - European Innovation Council

European Innovation Council - Sep 05, 2023

The biotech bi-weekly: sequencing costs slashed again, biomolecular interactions measured by the thousands and a single-cell picking platform for lipid profiles validated - BioTechniques

BioTechniques - Nov 06, 2024

Depixus Appoints Steve Klose as Chief Commercial Officer to Drive the Commercialization of Its Groundbreaking MAGNA™ Technology - BioSpace

BioSpace - Jan 11, 2024

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment